Segment and Geographic Information

9 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

Segment and Geographic Information

Segment and Geographic Information

The Company manages its business and operations as one segment and is focused on advancing the treatment of acute and intensive care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company allocates resources and assesses financial performance on a consolidated basis. Revenues reported to date are derived primarily from sales of Angiomax in the United States, including royalty revenue from Sandoz.

The geographic segment information provided below is classified based on the major geographic regions in which the Company operates. Long-lived assets are comprised of the Company’s noncurrent assets.

	Three Months Ended September 30,								Nine Months Ended September 30,
	2016				2015				2016				2015
					($ in thousands)
Net revenues:
United States	$	35,662	94.8	%	$	53,352	93.3	%	$	133,273	93.4	%	$	227,193	93.9	%
Europe	1,726		4.6	%	3,419		6.0	%	7,544		5.3	%	12,885		5.3	%
Rest of world	211		0.6	%	435		0.7	%	1,819		1.3	%	1,762		0.8	%
Total net revenues	$	37,599	100.0	%	$	57,206	100.0	%	$	142,636	100.0	%	$	241,840	100.0	%

	September 30, 2016				December 31, 2015
	($ in thousands)
Long-lived assets:
United States	$	1,053,737	99.5	%	$	956,298	99.3	%
Europe	5,525		0.5	%	6,301		0.7	%
Total long-lived assets	$	1,059,262	100.0	%	$	962,599	100.0	%